Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IBRX-042 |
| Synonyms | |
| Therapy Description |
IBRX-042 is a cancer vaccine comprising an adenoviral vector engineered to express HPV16-derived E6 and E7 proteins, which potentially induces a cytotoxic T-lymphocyte (CTL) response against HPV16 E6 and E7-expressing tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IBRX-042 | IBRX 42|IBRX042|hAd5-HPV E6.ETSD-IRES-E7.ETSD vaccine IBRX-042 | IBRX-042 is a cancer vaccine comprising an adenoviral vector engineered to express HPV16-derived E6 and E7 proteins, which potentially induces a cytotoxic T-lymphocyte (CTL) response against HPV16 E6 and E7-expressing tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05976828 | Phase I | IBRX-042 | IBRX-042 In Subjects With HPV-Associated Tumors | Active, not recruiting | USA | 0 |